晚期黑色素瘤：对现有疗法的耐药机制。
Advanced Melanoma: Resistance Mechanisms to Current Therapies.
机构信息
Department of Medicine, Vanderbilt University Medical Center, 719 Thompson Lane, Suite 20400, Nashville, TN 37204, USA.
Department of Medicine, Duke University Medical Center, 20 Duke Medicine Cir, Durham, NC 27710, USA.
出版信息
Hematol Oncol Clin North Am. 2021 Feb;35(1):111-128. doi: 10.1016/j.hoc.2020.09.005. Epub 2020 Oct 26.
Abstract
Novel therapeutic agents introduced over the past decade, including immune checkpoint inhibitors and targeted therapies, have revolutionized the management of metastatic melanoma and significantly improved patient outcomes. Although robust and durable responses have been noted in some cases, treatment is often limited by innate or acquired resistance to these agents. This article provides an overview of known and suspected mechanisms involved with acquired resistance to BRAF/MEK inhibitors as well as developing insights into innate and acquired resistance to checkpoint inhibitors in patients with melanoma.
摘要
过去十年中引入的新型治疗药物，包括免疫检查点抑制剂和靶向治疗药物，彻底改变了转移性黑色素瘤的治疗模式，并显著改善了患者的预后。尽管在某些情况下观察到了强大和持久的反应，但这些药物的治疗通常受到内在或获得性耐药的限制。本文概述了已知和可疑的与 BRAF/MEK 抑制剂获得性耐药相关的机制，并深入了解黑色素瘤患者对检查点抑制剂的内在和获得性耐药。
相似文献
1
Advanced Melanoma: Resistance Mechanisms to Current Therapies.晚期黑色素瘤：对现有疗法的耐药机制。
Hematol Oncol Clin North Am. 2021 Feb;35(1):111-128. doi: 10.1016/j.hoc.2020.09.005. Epub 2020 Oct 26.
2
Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.将 BRAF/MEK 抑制剂与免疫疗法联合用于治疗转移性黑色素瘤。
Am J Clin Dermatol. 2021 May;22(3):301-314. doi: 10.1007/s40257-021-00593-9. Epub 2021 Mar 25.
3
Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.突变 BRAF 和 MEK 抑制剂通过细胞焦亡调节肿瘤免疫微环境。
Cancer Discov. 2020 Feb;10(2):254-269. doi: 10.1158/2159-8290.CD-19-0672. Epub 2019 Dec 3.
4
Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.在接受检查点抑制剂治疗后，BRAF 突变转移性黑色素瘤初始进展时谨慎地添加靶向治疗联合 PD-1 抑制剂。
BMC Cancer. 2021 Nov 7;21(1):1187. doi: 10.1186/s12885-021-08906-1.
5
Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.BRAF 靶向黑色素瘤治疗耐药的机制。
Am J Clin Dermatol. 2021 Jan;22(1):1-10. doi: 10.1007/s40257-020-00572-6.
6
The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.晚期皮肤黑色素瘤患者的免疫检查点或 BRAF/MEK 抑制剂治疗与葡萄膜炎之间的关联。
Eur J Cancer. 2021 Feb;144:215-223. doi: 10.1016/j.ejca.2020.11.027. Epub 2020 Dec 26.
7
Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?黑色素瘤中针对BRAF靶向治疗的免疫反应：靶向治疗是免疫治疗吗？
Crit Rev Oncog. 2016;21(1-2):83-91. doi: 10.1615/CritRevOncog.2016017150.
8
Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.BRAF、MEK 和 CDK4/6 抑制剂的免疫调节作用：对联合靶向治疗和免疫检查点阻断治疗黑色素瘤的意义。
Front Immunol. 2021 May 7;12:661737. doi: 10.3389/fimmu.2021.661737. eCollection 2021.
9
MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.黑色素瘤中的 MAPK 通路 Ⅱ：BRAF 抑制的继发和适应性耐药机制。
Eur J Cancer. 2017 Mar;73:93-101. doi: 10.1016/j.ejca.2016.12.012. Epub 2017 Feb 3.
10
Combinatorial Approaches to the Treatment of Advanced Melanoma.联合治疗晚期黑色素瘤。
Hematol Oncol Clin North Am. 2021 Feb;35(1):145-158. doi: 10.1016/j.hoc.2020.08.015. Epub 2020 Oct 26.
引用本文的文献
1
Immune profiling in oncology: bridging the gap between technology and treatment.肿瘤学中的免疫分析：弥合技术与治疗之间的差距。
Med Oncol. 2025 Aug 26;42(10):446. doi: 10.1007/s12032-025-03002-x.
2
Vemurafenib and Dabrafenib Downregulates RIPK4 Level.维莫非尼和达拉非尼下调RIPK4水平。
Cancers (Basel). 2023 Feb 1;15(3):918. doi: 10.3390/cancers15030918.
3
Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies.抗体药物偶联物治疗黑色素瘤和其他皮肤恶性肿瘤。
Curr Treat Options Oncol. 2022 Oct;23(10):1428-1442. doi: 10.1007/s11864-022-01018-3. Epub 2022 Sep 20.
4
Salviolone from Roots Impairs Cell Cycle Progression, Colony Formation, and Metalloproteinase-2 Activity in A375 Melanoma Cells: Involvement of P21(Cip1/Waf1) Expression and STAT3 Phosphorylation.从根中提取的柳穿鱼素可抑制 A375 黑素瘤细胞的细胞周期进程、集落形成和金属蛋白酶-2 活性：涉及 P21(Cip1/Waf1)表达和 STAT3 磷酸化。
Int J Mol Sci. 2022 Jan 20;23(3):1121. doi: 10.3390/ijms23031121.
5
Molecular Alterations Associated with Acquired Drug Resistance during Combined Treatment with Encorafenib and Binimetinib in Melanoma Cell Lines.黑色素瘤细胞系中恩考芬尼和比美替尼联合治疗期间与获得性耐药相关的分子改变
Cancers (Basel). 2021 Dec 1;13(23):6058. doi: 10.3390/cancers13236058.
本文引用的文献
1
Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review).抗肿瘤 PD-1/PD-L1 阻断的预测性生物标志物的机制见解：免疫组学评估的范式转变（综述）。
Oncol Rep. 2020 Aug;44(2):424-437. doi: 10.3892/or.2020.7643. Epub 2020 Jun 11.
2
Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients.抗 PD-1 检查点抑制剂治疗肢端黑色素瘤：193 例日本患者的多中心研究。
Ann Oncol. 2020 Sep;31(9):1198-1206. doi: 10.1016/j.annonc.2020.05.031. Epub 2020 Jun 6.
3
TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma.TLR9 激活与 T 细胞检查点阻断协同作用，使免疫原性差的黑色素瘤消退。
J Immunother Cancer. 2019 Nov 26;7(1):323. doi: 10.1186/s40425-019-0811-x.
4
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.AXL 受体酪氨酸激酶作为一种有前途的抗癌方法：功能、分子机制和临床应用。
Mol Cancer. 2019 Nov 4;18(1):153. doi: 10.1186/s12943-019-1090-3.
5
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.先前抗生素治疗与癌症患者免疫检查点抑制剂治疗的生存和应答的相关性。
JAMA Oncol. 2019 Dec 1;5(12):1774-1778. doi: 10.1001/jamaoncol.2019.2785.
6
Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence.免疫治疗下黑色素瘤反应的蛋白质组学研究揭示了线粒体的依赖性。
Cell. 2019 Sep 19;179(1):236-250.e18. doi: 10.1016/j.cell.2019.08.012. Epub 2019 Sep 5.
7
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.达拉非尼联合曲美替尼治疗转移性黑色素瘤的 5 年结果。
N Engl J Med. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4.
8
Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?免疫检查点阻断的耐药机制：为何检查点抑制剂免疫疗法并非对所有患者都有效？
Am Soc Clin Oncol Educ Book. 2019 Jan;39:147-164. doi: 10.1200/EDBK_240837. Epub 2019 May 17.
9
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with -mutated Metastatic Melanoma.携带 - 突变的转移性黑色素瘤患者接受威罗菲尼 ± 考比替尼治疗的卓越反应的基因组特征。
Clin Cancer Res. 2019 Jun 1;25(11):3239-3246. doi: 10.1158/1078-0432.CCR-18-0720. Epub 2019 Mar 1.
10
Melanoma vaccines: clinical status and immune endpoints.黑色素瘤疫苗：临床现状与免疫终点
Melanoma Res. 2019 Apr;29(2):109-118. doi: 10.1097/CMR.0000000000000535.
Zotero 插件